Matches in Wikidata for { <http://www.wikidata.org/entity/Q89612201> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q89612201 description "artículu científicu espublizáu en marzu de 2020" @default.
- Q89612201 description "scientific article published on 01 March 2020" @default.
- Q89612201 description "wetenschappelijk artikel" @default.
- Q89612201 description "наукова стаття, опублікована 1 березня 2020" @default.
- Q89612201 name "Response to Letter to the Editor: "Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care"" @default.
- Q89612201 name "Response to Letter to the Editor: "Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care"" @default.
- Q89612201 type Item @default.
- Q89612201 label "Response to Letter to the Editor: "Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care"" @default.
- Q89612201 label "Response to Letter to the Editor: "Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care"" @default.
- Q89612201 prefLabel "Response to Letter to the Editor: "Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care"" @default.
- Q89612201 prefLabel "Response to Letter to the Editor: "Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care"" @default.
- Q89612201 P1433 Q89612201-9905F5D6-EBB9-44F1-BC7F-E84F9C59510F @default.
- Q89612201 P1476 Q89612201-8653BE75-5370-4A09-8B38-48FC3F80AE4A @default.
- Q89612201 P2093 Q89612201-392CD1C8-B70D-4959-BEC9-2C65FE55989C @default.
- Q89612201 P2093 Q89612201-74E87C67-1B3E-41E7-BF35-E2EEF4B74DD4 @default.
- Q89612201 P2093 Q89612201-DDF6E456-BD81-486F-B3BC-76ADC5F01FEB @default.
- Q89612201 P2093 Q89612201-FB7973AB-5C6D-4D57-9F0F-57B5C61F22DC @default.
- Q89612201 P2093 Q89612201-FE217A1C-25AC-4B52-A946-943747729AAE @default.
- Q89612201 P31 Q89612201-B8692210-7DA9-43D9-8926-CEBC66EDA67C @default.
- Q89612201 P356 Q89612201-B79CB674-6311-4083-B8E8-DA83DEF2744B @default.
- Q89612201 P433 Q89612201-5D06895C-650C-4C52-9FD8-B44C58ED5184 @default.
- Q89612201 P478 Q89612201-D61D656A-0D9A-408F-B192-F5B7DC03AC0A @default.
- Q89612201 P577 Q89612201-4D6134A8-3C03-499B-8825-C807BE07FBE1 @default.
- Q89612201 P698 Q89612201-CCC8A627-D444-4C3B-B2EC-98D7C60035B3 @default.
- Q89612201 P356 DGZ135 @default.
- Q89612201 P698 32036387 @default.
- Q89612201 P1433 Q3186902 @default.
- Q89612201 P1476 "Response to Letter to the Editor: "Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care"" @default.
- Q89612201 P2093 "Antonio Nicolucci" @default.
- Q89612201 P2093 "Gabriele Riccardi" @default.
- Q89612201 P2093 "Giuseppe Lucisano" @default.
- Q89612201 P2093 "Maria Masulli" @default.
- Q89612201 P2093 "Olga Vaccaro" @default.
- Q89612201 P31 Q13442814 @default.
- Q89612201 P356 "10.1210/CLINEM/DGZ135" @default.
- Q89612201 P433 "3" @default.
- Q89612201 P478 "105" @default.
- Q89612201 P577 "2020-03-01T00:00:00Z" @default.
- Q89612201 P698 "32036387" @default.